4//SEC Filing
DALTON MARK F 4
Accession 0001125282-03-005265
CIK 0000835887other
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 7:23 PM ET
Size
14.0 KB
Accession
0001125282-03-005265
Insider Transaction Report
Form 4
DALTON MARK F
Director
Transactions
- Award
Stock Option (Right to Buy)
2003-04-01+2,500→ 2,500 totalExercise: $4.41From: 2003-04-01Exp: 2013-03-31→ Common Stock (2,500 underlying) - Award
Stock Option (Right to Buy)
2003-07-01+10,000→ 10,000 totalExercise: $15.06From: 2003-07-01Exp: 2013-06-30→ Common Stock (10,000 underlying)
Holdings
- 68,000
Common Stock, par value $0.0013 per share ("Common Stock")
- 16,500(indirect: By DF Partners)
Common Stock, par value $0.0013 per share ("Common Stock")
- 2,342,388(indirect: By Tudor Group)
Common Stock, par value $0.0013 per share ("Common Stock")
Footnotes (3)
- [F1]The Reporting Person disclaims beneficial ownership of the securities reported herein as indirectly owned except to the extent of his pecuniary interest in such securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his pecuniary interest in such securities, for purposes of Section 16 or for any other purpose.
- [F2]See Remarks.
- [F3]The Reporting Person is the General Partner of DF Partners.
Issuer
PROGENICS PHARMACEUTICALS INC
CIK 0000835887
Entity typeother
Related Parties
1- filerCIK 0001250267
Filing Metadata
- Form type
- 4
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 7:23 PM ET
- Size
- 14.0 KB